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ABSTRACT
THE EFFECT OF NALTREXONE ON NICOTINE-INDUCED CONDITIONED
PLACE PREFERENCE IN RATS
By
Jonathan M. Adams
Nicotine is the central active ingredient in tobacco. The reinforcing effects of nicotine
can be studied in animals through self-administration, conditioned place preference, and
other approaches that enable researchers to assess nicotine cessation strategies. One
strategy involves the use of opioid receptor antagonists. For instance, naloxone has been
shown to reduce place preference for nicotine in rats, and other experimental opioid
antagonists have also been shown to affect place preference for nicotine. The present
study sought to extend these findings to the opioid antagonist naltrexone, which has long
been FDA-approved for the treatment of opioid and alcohol addiction in humans. Using
standard two-chamber shuttleboxes, we first sought to establish a place preference for
nicotine in rats, and once this was achieved, we sought to block nicotine place preference
with naltrexone. In the first experiment, subjects did not show a place preference for
nicotine, but an alteration in the environmental stimuli used on the shuttleboxes led to a
conditioned place preference for nicotine in the second experiment. In the third
experiment, naltrexone did not block nicotine place preference. These results coincide
with past findings that indicate a difficulty to establish a conditioned place preference for
nicotine. This paper discusses these challenges and suggests other ways to evaluate a
potential use for opioid receptor antagonists for treating nicotine addiction.
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INTRODUCTION
First- and second-hand tobacco exposure has been the subject of a barrage of
public health warnings and ad campaigns over the past several decades due to links to
cardiovascular disease, chronic obstructive pulmonary disease, and several varieties of
cancer – most notably lung cancer, but also cancer of the mouth, pharynx, esophagus,
kidneys, bladder, and other cancers (CDC, 2012). According to Benowitz (2010), an
average of 435,000 Americans die of smoking-related ailments per year (accounting for
one out of every five deaths), and the average lifelong tobacco smoker has a 50% chance
of dying prematurely from a tobacco-related cause. In addition to the deleterious health
effects of smoking, another potential issue with tobacco use is its potential for interaction
with other drugs – especially with prescription medications. For instance, Porter, Heath,
and Rosecrans (1994) found that nicotine can reduce the anxiolytic effects of the
benzodiazepine diazepam, which means, for example, that a person suffering from
anxiety may inadvertently negate the effects of his or her anxiety medication by smoking.
Seventy percent of smokers claim that they want to quit, but less than 5% do so
successfully (Benowitz, 2010). Thus, a major dilemma is how to develop treatment
strategies for smokers and other tobacco users to successfully quit using these harmful
products. While a small proportion of tobacco users are able to quit smoking by simply
ceasing use (quitting "cold turkey"), the one-year abstinence rate for smokers who quit on
their own without help is only 6 percent (Livingston & Lynm, 2012). One of the major
issues in the treatment of any substance use disorder is known as protracted withdrawal
syndrome, or post-acute-withdrawal syndrome. Chronic drug use results in
neuroadaptations involving a wide variety of neurotransmitters and brain circuits,
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including those underlying motivation and decision making (Paolini & De Biasi, 2011;
Zorrilla, Valdez, & Weiss, 2001). These adaptations result in widespread changes in
neurotransmission, and the brain essentially establishes a new equilibrium in response to
constant drug exposure. Withdrawal refers to the collection of somatic and affective
symptoms that occur when this drug-specific equilibrium is disrupted, as in the case of
drug cessation. Nicotine withdrawal symptoms can include concentration problems,
irritability, anxiety, depression, and insomnia, and these symptoms can overwhelm the
recently abstinent smoker and drive him or her to resume smoking in order to alleviate
these unpleasant symptoms (Paolini & De Biasi, 2011).
In the case of post-acute-withdrawal syndrome, some symptoms may continue to
persist for a much longer period of time than the typical acute withdrawal period, which
can affect long-term abstinence success rates. Post-acute withdrawal syndrome is known
to occur for several drugs of abuse, most notably alcohol, with which some withdrawal
symptoms can be seen as long as 4 years following cessation of alcohol use (LeBon,
Murphy, Staner et al., 2003). There is some evidence that post-acute-withdrawal
symptoms may occur to some extent with nicotine as well, as evidenced by reports of
nicotine craving 6 months following smoking cessation (Hughes, 1994).
One of the major avenues of treating substance abuse is through medication, or
pharmacotherapy, which is often used as an adjunct to more traditional means of
treatment, and has proven in recent years to be a very promising area for those who are
seeking improved ways of treating substance abuse and dependence, either as a
standalone treatment or in conjunction with other forms of treatment as part of a more
holistic, comprehensive approach. Several different pharmacotherapies have been
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developed for smoking cessation and are classified into three types: nicotine-replacement
therapy, nicotinic-receptor agonists, and antidepressant drugs (Polosa & Benowitz, 2011).
Nicotine replacement therapy attempts to relieve the withdrawal symptoms of
smoking cessation by providing an alternative source of tobacco-free nicotine via a skin
patch, lozenge, nasal spray, chewing gum, or a variety of other delivery methods, many
of which are available over-the-counter. The eventual goal of nicotine replacement
therapy is for the user to follow a schedule to gradually wean him-or-herself off of the
product so that they can be not only tobacco-free, but nicotine-free as well.
Unfortunately, the 6-month smoking abstinence rate for over-the-counter nicotine
replacement therapy is less than 10% (Lee & Tyndale, 2006). According to Basham and
Luik (2012), some recent studies have indicated that nicotine replacement therapy may
even be less effective than simply quitting tobacco use “cold turkey” without assistance.
However, some prefer an approach to tobacco cessation that does not involve the
continued use of nicotine, which is where alternative pharmacotherapies come in. One
such approach involves the use of antidepressant drugs. According to Hughes, Stead,
Hartmann-Boyce, Cahill, and Lancaster (2014), there are three primary reasons why
antidepressant drugs may be effective in aiding tobacco cessation: 1.) nicotine withdrawal
may cause depressive symptoms that would be alleviated by antidepressant drugs; 2.)
nicotine itself may serve as an antidepressant drug of sorts, thus antidepressant drugs may
serve as an effective substitute in this capacity; and 3.) it is possible that some
antidepressant drugs may affect the same neural pathways or receptors that underlie
nicotine addiction (i.e.- they may inhibit monoamine oxidase or block nicotinic
receptors). However, buproprion (Wellbutrin, Zyban), the most commonly prescribed
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antidepressant drug for nicotine dependence, has shown to produce a 12-month tobacco
abstinence rate of less than 25% (Lee & Tyndale, 2006).
Another nicotine-free approach involves nicotinic receptor agonists, which reduce
the activation of the specific receptors that nicotine binds to in the brain, lessening the
pharmacological effects produced by nicotine intake, as well as reducing cravings. In
other words, when a tobacco user smokes a cigarette, he or she doesn't experience the
same pleasurable effects as usual, thus rendering smoking less enjoyable. The first
nicotinic receptor agonist to be FDA-approved for clinical use was the nicotinic α4β2
partial agonist varenicline (Chantix). However, this strategy has not been shown to be
overly successful either, as it has been shown to reduce tobacco use in less than 50% of
smokers (Gonzales et al., 2006; Polosa & Benowitz, 2011).
Research has indicated that opioid receptors also may play a role in certain
aspects of nicotine addiction (Jackson, Carroll, Negus, & Damaj, 2010; King & Meyer,
2000; Liu, et al., 2009; Rustkalis et al., 2005; Smith et al., 2005; Trigo, Martin-Garcia,
Berrendero, Robledo, & Maldonado, 2010), which suggests that opioid receptor
compounds may have utility for the treatment of nicotine addiction. In their
comprehensive review of research involving the endogenous opioid system, Trigo and
colleagues (2010) conclude that opioid receptors (primarily mu-opioid receptors, and to a
lesser extent, delta-opioid receptors) are indeed critically involved in the rewarding
properties of a variety of different drugs, including nicotine. Early proof of concept
investigations will likely involve opioid compounds that have been FDA approved, and
thus already screened through toxicology testing, for other purposes. The opioid receptor
antagonist naltrexone has been FDA-approved as a treatment option for both opioid and
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alcohol-use disorders, leading to a variety of studies that have examined the potential of
this drug as a treatment for a variety of other substance use disorders (Modesto-Lowe &
Van Kirk, 2002). As we will see in the following sections, results suggest that opioid
receptor antagonism may be useful in the treatment of nicotine addiction, but naltrexone
has yet to be FDA-approved as treatment option for anything but alcohol and opioids, so
further research is warranted. Before exploring its relationship with nicotine, let us first
examine naltrexone's method of action in the body and its application to substance abuse
treatment in general.
Pharmacodynamics of Naltrexone
Naltrexone is one of three clinically available opioid antagonists, with the other
two being naloxone (which is very short-lasting and used primarily for tests of opioid
dependence or intervention in cases of opioid overdose) and nalmefene (which is used
primarily in cases of opioid overdose to treat acute respiratory depression). Naltrexone is
a nonselective opioid receptor antagonist, in that it binds with three of the primary
subtypes of opioid receptors (Jayaram-Lindstrom, Konstenius, Eksborg et al., 2008;
Mannelli, Peindl, Masand, & Patkar, 2007). According to Mannelli and colleagues
(2007), naltrexone has the highest affinity for mu-opioid receptors (receptor binding Ki:
0.37 nM), but also has an affinity for kappa-opioid receptors (4.8 nM) and for deltaopioid receptors (9.4 nM).
Naltrexone and Opioids
Like the older opioid receptor antagonist naloxone, naltrexone administration
precipitates withdrawal symptoms in opioid-dependent users by blocking the acute
effects of opioid agonists. Whereas the shorter-acting naloxone is typically used to
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counteract the effects of opioid overdose in current opioid users (McMenamin, 2012), the
longer-acting naltrexone may be more suitable as a maintenance treatment for recently
abstinent opioid-dependent users. Long-term naltrexone treatment not only blocks the
intoxicating and rewarding effects of opioids in the case of relapse, but is also viewed by
some as a safer and more socially acceptable option than traditional opioid agonist
treatments (i.e.- methadone), as it provides no euphoric effects and is not addictive
(Krupitsky et al., 2011; Sullivan et al., 2006).
Olmstead and Burns (2005) studied the effects of naltrexone administration on
opioid withdrawal in rats, using conditioned place preference and conditioned place
aversion paradigms. They found that co-administration of naltrexone in ultra-low-doses
(5 ng/kg and 30 pg/kg) blocked the acute rewarding effects of oxycodone and morphine,
respectively, as well as the anhedonic withdrawal symptoms associated with long-term
administration of both drugs. However, in human subjects, Tompkins et al. (2010) found
that co-administering ultra-low-dose naltrexone with oxycodone did not decrease abuse
liability in experienced opioid abusers. According to Duggan and Lesley (2010), this
may have something to do with medical compliance and route of administration. They
studied the effects of a new anti-abuse delivery method that combines morphine and
naltrexone in a single capsule. In the event that the capsule is tampered with (i.e. crushed for purposes of intranasal or intravenous administration), naltrexone is rapidly
released and absorbed, completely blocking the effects of morphine.
Sullivan et al. (2006) studied the effects of injectable depot naltrexone (another
delivery method designed to reduce abuse liability and medical non-compliance) on
clinical outcomes for heroin dependence in humans. They found that 384 mg of
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naltrexone delivered via intramuscular injection blocked both the subjective and
reinforcing effects of heroin for up to five weeks. After the second week, subjective
ratings of withdrawal declined significantly, and the effects of administered heroin
(measured by pupil diameter) did not begin to re-emerge until the fifth week. Krupitsky
et al. (2011) also found support for the use of injectable naltrexone for opioid
dependence. Compared to placebo (35%), depot naltrexone resulted in a 90% abstinence
rate (confirmed by urine testing), -10.1% change in craving (vs. +0.7% in the placebo
group), and longer treatment retention (168 days for naltrexone vs. 96 days for placebo).
Naltrexone and Alcohol
While opioid receptor antagonists are used in the treatment of opioid dependence,
the first FDA-approved use for naltrexone was as a treatment for alcohol dependence.
Srisurapanont and Jarusaraisin (2005) performed a meta-analysis of 24 studies (with a
total of 2,861 human subjects) that assessed naltrexone for the treatment of alcoholism
prior to 2005. They found that for short-term treatment, naltrexone did not decrease
discontinuation of treatment, but did significantly decrease the incident of relapse. They
concluded that, while the perfect duration length for treatment is not yet known,
naltrexone should be strongly considered as a viable short-term treatment option for
alcoholism, and some form of adjunct psychosocial therapy should be used with all
patients receiving naltrexone in order to maximize positive treatment outcomes.
Deas, May, Randall, Johnson, and Anton (2005) examined naltrexone treatment
outcomes in adolescent alcoholics in an open-label pilot study. The average number of
daily drinks for subjects per drinking day decreased significantly from baseline over a
six-week period, suggesting that naltrexone administration may result in significant
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decreases in both craving and use. They found that alcohol-dependent adolescents
tolerated naltrexone well, with the same minor side effects that occur in adults, and
concluded that naltrexone would be a viable option in the treatment of adolescent alcohol
disorders.
Peterson, Conrod, Vassileva, Gianoulakis, and Pihl (2006) studied the effects of
naltrexone on the physiological, behavioral, and subjective effects of acute alcohol
intoxication. They found that when alcohol was administered, naltrexone had a
significant effect on blood-alcohol concentration, reduced the characteristic heart rate
increase of alcohol intoxication, and accounted for changes in the subjects' subjective and
behavioral responses to alcohol. A major finding was that naltrexone specifically
blocked the stimulant properties of alcohol that characteristically appear during early
acute intoxication.
Weerts et al. (2008) used positron emission tomography to measure opioid
receptor blockade in 21 recently abstinent alcohol-dependent subjects who were being
treated with naltrexone. They found almost complete blockade of mu-opioid receptors,
along with partial blockade of delta-opioid receptors in all subjects. This finding is
significant because these two subtypes of opioid receptors are thought to be instrumental
in modulating the reinforcing properties of alcohol and the maintenance of alcohol
consumption. Not coincidentally, it is known that rodent strains which show preference
for alcohol display differences in receptor density for these two subtypes (Weerts et al.,
2008). For instance, Marinelii, Kiianmaa, and Gianoulakis (2000) observed a
significantly higher degree of mu-opioid receptor binding in the shell of the nucleus
accumbens and in the prefrontal cortex of selectively bred AA (alko, alcohol) rats than in
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ANA (alko, non-alcohol) rats. McBride, Chernet, McKinzie, Lumeng, and Li (1998)
observed mu-opioid receptor density in alcohol-preferring rats to be approximately 20 %
higher in the olfactory tubercle and the nucleus accumbens, 25 % higher in the
basolateral and lateral nuclei of the amygdala, 15% higher in the caudate-putamen, and
between 10 and 30 % lower in the hippocampus than in the non-alcohol-preferring strain.
Soini, Ovaska, Honkanen, Hyttia, and Korpi (1998) found that overall delta-opioid
receptor density was significantly lower in the brains of AA rats versus ANA rats. Soini
and colleagues (1998) suggest that differences in receptor density and distribution in
brain regions associated with cognition, emotion, and motivation may be neurochemical
correlates of differences in alcohol-drinking behavior between different animal strains.
However, McBride and colleagues (1998) note that opioid receptors are likely just one
small part of a much larger and more complex system involved in mediating alcohol use,
and caution that our current understanding of how alcohol use is mediated only allows for
acknowledgement of a correlation between opioid receptor density and propensity for
alcohol use.
In addition to trials with human subjects, the effects of naltrexone on alcohol
consumption and effects has also been studied in laboratory animals. Varashin et al.
(2005) studied the effects of the microinjection of naltrexone into the nucleus accumbens
of rats. They found that pretreatment with naltrexone prevented the development of
tolerance to the motor effects of alcohol, adding further evidence to the idea that the
opioid system is involved in the development of tolerance to the effects of alcohol.
Czachowski and Delory (2009) studied the treatment effects of naltrexone and
acamprosate (a drug that is known to decrease glutamate levels and increase beta-
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endorphin release [Kalk & Lingford-Huges, 2014]) on alcohol seeking and drinking
versus sucrose seeking and drinking in alcohol-dependent and nondependent rats. They
found that naltrexone decreased alcohol seeking and consumption in nondependent rats.
The researchers hypothesized that the "nondependent" group could model early-stage
problem drinking in humans, therefore suggesting that naltrexone could be used for
purposes of intervention at this stage of drinking, in addition to relapse prevention for
newly abstinent alcohol-dependent patients.
Naltrexone and Nicotine
In addition to its approved uses for the treatment of alcohol and opioid
dependence, other studies have investigated naltrexone's effect on other drugs of abuse.
While it has been established that nicotinic receptors and the dopamine system are
involved in nicotine addiction (Gonzales, Rennard, Nides et al., 2006; Benowitz, 2010),
the role of opioid receptors has also become an area of interest in nicotine research
(Walters, Cleck, Kuo, & Blendy, 2005). As is the case with alcohol abuse and
dependence, the opioid system is thought to play a major role in mediating the effects of
stimulant drugs, and research has been conducted to investigate this assumption. For
instance, Campbell, Taylor, and Tizabi (2007) found that the selective opioid antagonists
D-Phe–Cys–Tyr–D-Trp–Arg–Thr–Pen–Thr-NH2 (CTAP), which is selective for muopioid receptors, naltrindole (selective for delta-opioid receptors), and
norbinaltorphimine (selective for kappa-opioid receptors) were each successful in
blocking the antinociceptive effects of nicotine and/or alcohol in Wistar rats. Jackson et
al. (2010) similarly found that pretreatment with the highly selective kappa-opioid
receptor antagonist JDTic ((3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)-
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3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro-3isoquinolinecarboxamide) attenuated physical and affective signs of nicotine withdrawal
in mice, and concluded that kappa-opioid receptors are clearly involved in mediating
nicotine withdrawal symptoms. This builds upon the findings of Todtenkopf, Marcus,
Portoghese, and Carlezon (2004) that the stimulation of kappa-opioid receptors in the
brain triggers depressive-like symptoms in animal subjects, as well as Todtenkopf and
colleagues’ (2004) suggestion that kappa-opioid antagonists may have efficacy as
antidepressants.
In addition to the aforementioned opioid receptor antagonists, the effect of
naltrexone on nicotine use has also been studied. For instance, Krishnan-Sarin,
Meandzija, and O'Malley (2003) found in a small-sample preliminary study that
naltrexone showed potential as a very promising treatment option: it decreased incident
of relapse and reduced smokers' desires to smoke tobacco. King and Meyer (2000) found
that nicotine-dependent subjects reported reduced cravings and desire to smoke when
given oral naltrexone. Rustkalis et al. (2005) studied the effect of naltrexone
pretreatment on human cigarette smokers. They found that the relative reinforcing value
of nicotine via cigarette smoking was significantly lower following administration of
naltrexone, and concluded that further investigation of opioid receptor antagonists as a
possible component of smoking cessation programs is warranted based on these results.
Rohsenow et al. (2007) concluded that higher-dose transdermal nicotine replacement
therapy (i.e., the "nicotine patch") was a more promising smoking cessation treatment
than naltrexone, but other subsequent studies have shown further support for the use of
naltrexone in the treatment of nicotine addiction.
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Liu et al. (2009) studied whether treatment with naltrexone has an effect on the
conditioned incentive salience of nicotine cues in rats. They found that naltrexone
attenuated cue-induced reinstatement of nicotine-seeking after extinction had taken place,
but that naltrexone did not affect nicotine self-administration behavior. These results
indicate that naltrexone may be useful in the prevention of cue-induced relapse to
cigarette smoking in recently abstinent nicotine addicts. This discrepancy may also
indicate that the conditioned place preference paradigm has higher ecological validity as
an approximation of human nicotine-seeking behavior than the self-administration
paradigm.
Other studies have examined the effect of naltrexone on nicotine in the context of
alcohol use. For instance, Ray et al. (2007) studied the effects of alcohol and naltrexone
on nicotine craving in light smokers. They found that while the pharmacological effects
of alcohol itself induced craving for nicotine, naltrexone greatly lessens the cigarette
craving during alcohol use. These researchers concluded that naltrexone is effective for
reducing smoking in heavy drinkers. Likewise, O'Malley et al. (2009) studied the effect
of naltrexone therapy on the reduction of hazardous alcohol use by subjects during a trial
of naltrexone for smoking cessation. Their findings suggest that naltrexone may be able
to lessen the risk of hazardous drinking in people who both drink alcohol and smoke
cigarettes and are not attempting to reduce their alcohol consumption (by treatment
enrollment or otherwise).
Nicotine and Incentive Salience
There are several different aspects to, or types of, reward that are involved in drug
addiction. One type of reward can be called hedonic pleasure, or hedonic impact, which
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refers to "liking" something-- in other words, finding a food, drug, or activity to be
palatable or subjectively pleasurable upon experiencing it. Another aspect of reward is
incentive salience, which, in the case of drug use and dependence, involves associating
external stimuli, or cues, with taking the drug, causing a “wanting” (Zhang, Berridge,
Tindell, Smith, & Aldridge, (2009).
This is important in the study of drug addiction for several reasons. Hedonic
"liking" is often associated with drug use or abuse, where a person (or laboratory animal)
engages in use of a drug for its pleasurable effects. "Wanting," on the other hand, which
is where incentive salience comes in, is characteristic of experienced drug users who
already have assigned a positive valence to the drug and are able to make predictions
about what will happen when they obtain the drug and self-administer it. This “wanting”
can result in motivation to continue using a drug even if the drug’s hedonic impact
(“liking”) has been suppressed by tolerance. Additionally, “wanting” may continue to
persist when drug-related cues are present even if predictions about the drug’s value have
become negatively valenced, such as in the case of “recovering addicts” who have
experienced significant adverse consequences of their drug use (Smith, Berridge, &
Aldridge, 2011).
A basic way to describe incentive salience is to say that it is a motivational
property that involves an intense "pulse" of "wanting" that is triggered by a cue, and is
modulated by internal physiological states such as drug withdrawal (Zhang, Berridge,
Tindell, Smith, & Aldridge, 2009). For chronic tobacco smokers, this may appear as
wanting tobacco in situations or circumstances when they normally smoke, as nicotine is
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very effective in establishing or magnifying the incentive and reinforcing properties of
environmental stimuli associated with smoking (Caggiula et al., 2001).
Smith, Berridge, and Aldridge (2011) investigated signals for these different
aspects of reward in the nucleus accumbens and ventral palladium in rats, using
microinjections of drugs that stimulated either opioid or dopamine receptors. They
concluded that signals for hedonic pleasure (liking) and incentive salience
(wanting/motivation), as well as Pavlovian prediction (learning), are all separate and
distinguishable processes in the mesocorticolimbic circuits of the nucleus accumbens and
ventral palladium. Stimulation of the dopamine system increased motivation (wanting),
but did not affect liking or learning signals. Stimulation of the opioid system, on the
other hand, increased both liking signals and incentive salience signals. The fact that
there is evidence for separate, distinguishable pathways in the brain for each of these
aspects of drug reward, and evidence that different neurotransmitters may play specific
roles in each aspect of reward is an exciting revelation that has significant implications
for nicotine-related pharmacotherapy research. Additionally, this study implies that the
opioid system may play just as large a role in mediating nicotine addiction as does the
dopamine system, which would help to explain and further validate the results of the
previously mentioned studies on the effect of naltrexone on nicotine dependence.
Conditioned Place Preference
A common procedure used to measure the behavioral effects of drugs in
laboratory animals is conditioned place preference, which involves assigning
motivational properties to specific “places,” via reward pairing. In this paradigm, the
stimuli within a specific environment, or place, become associated with a drug’s
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reinforcing effects through repeatedly pairing the drug’s reinforcing effects with the
environment. A “place preference” is evidenced by the animal spending a larger amount
of time in the reward-paired environment, or place, than it did previous to the association
of that environment with the reward (Calcagnetti & Schechter, 1994). Thus, it has been
speculated that when a drug is rewarding to an animal, a specific place that has been
paired with that drug may acquire an incentive motivational property that results in the
animal “preferring” it to places that have not been paired with the drug (Flagel, Akil, &
Robinson, 2009).
A typical conditioned place preference procedure involves administering a drug to
a subject (i.e. - via injection) and confining it to one stimulus-distinct compartment of a
shuttlebox, which consists of two or three compartments and is normally used for
conditioned place preference procedures in rodents. This is repeated daily, with the
caveat that every other day the animal is administered a control (i.e. - saline injection
without the drug) and placed in the stimulus-distinct compartment on the opposite side of
the apparatus. Then, during the testing phase, the animal is not given the drug and the
researcher measures how much time the animal spends in each compartment. If the
animal spends more time in the compartment where the drug was administered, it can be
inferred that the animal "likes" the drug and prefers to spend time in the compartment that
it associates with the effects of the drug. In this case, conditioned place preference is said
to have occurred. It is also possible that the animal found the effects of the drug aversive,
and may choose to spend less time in the compartment associated with the drug. If this
occurs, it is known as conditioned place aversion (Calcagnetti & Schechter, 1994).
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Conditioned Place Preference with Nicotine
Numerous studies have evaluated nicotine in the conditioned place preference
paradigm. Conditioned place preference with nicotine dates back at least as far as Fudala
et al (1985) and Fudala and Iwamoto (1986), who found that nicotine induced
conditioned place preference in rats. After a number of additional studies by other
researchers in the late 1980s and early 1990s produced conflicting results in
demonstrating place preference for nicotine, Calcagnetti and Schechter (1994) focused on
conducting a conditioned place preference experiment with a biased approach that
utilized baseline preference assessments prior to drug pairing. With the biased approach,
the drug being studied is paired with each individual animal’s less-preferred shuttlebox
chamber; thus it takes into account individual differences between subjects, which is
thought to increase both the validity and the reliability of the conditioned place
preference paradigm.
Walters, Brown, Changeaux, Martin, and Damaj (2006) further investigated the
mechanisms underlying the reinforcing properties of nicotine using a conditioned place
preference paradigm in wild-type mice. They found that pretreatment with the [alpha]-4[beta]-2 subunit of the nicotinic acetylcholine receptor antagonist dihydro-[beta]erythroidine blocked conditioned place preference for nicotine in their animal subjects.
In addition to nicotinic receptors, opioid receptors may also play a role in
nicotine’s conditioned place preference effects. For instance, Walters et al. (2005) used
conditioned place preference in an experiment that looked at the relationship between
nicotine, naloxone, and the transcription factor CREB. Walters and colleagues (2005)
further investigated previous findings that nicotine causes a release of endogenous
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opioids in different parts of the brain in rats and mice, and found that a single
administration of the opioid-receptor antagonist naloxone blocked the conditioned
behavioral response of nicotine reward in a conditioned place preference paradigm.
Zarrindast, Faraji, Rostami, Sahraei, and Ghoshouni (2003) found that naloxone blocked
place preference for both nicotine and morphine in mice.
Smith et al. (2012) specifically investigated the involvement of the
dynorphin/kappa-opioid system in nicotine addiction. They found that nicotine indeed
produces conditioned place preference in mice, and found that place preference for
nicotine was blocked by the opioid receptor antagonist norbinaltorphimine. They also
stress the validity of comparing conditioned place preference in animal models to
nicotine-related human behaviors by pointing out that activation of the kappa-opioid
system elicits similar dysphoric responses and anxious behaviors in both humans and
rodents.
Rationale
The opioid-receptor antagonist naltrexone, which is approved as a
pharmacotherapy for the treatment of opioid dependence and alcohol dependence, has
more recently been examined as a possible treatment for dependence on other drugs of
abuse. As we have seen in the preceding sections, there exists compelling evidence that
opioid receptors play a role in mediating the conditioned place preference effects of
nicotine, and it has been demonstrated that the opioid receptor-antagonist naloxone can
block place preference for nicotine. Since naltrexone has proven promising in the
treatment of dependence on other drugs, we believe that further evaluation of naltrexone
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as a pharmacotherapy for nicotine dependence is warranted, and the best way to do this in
an animal model is by utilizing the conditioned place preference paradigm.
Method
Experiment 1
Subjects. Forty male Sprague-Dawley rats (Charles River Laboratories, Portage,
MI) weighing at least 250 g were used for this experiment. Rats were group housed and
provided food and water ad lib in their home cages. All procedures were approved by the
Institutional Animal Care and Use Committee for Northern Michigan University and
followed the Guide for the Care and Use of Laboratory Animals, 2nd edition (2012).
Animals were kept on a 12-hour light/dark cycle (lights on at 11:00 a.m. and off at 11:00
p.m.), and were housed in a temperature-controlled room adjacent to the testing room.
Drugs. Both naltrexone hydrochloride (Sigma-Aldrich, St. Louis, MO) and
nicotine hydrochloride (Sigma-Aldrich) were dissolved in a 0.9% physiological saline
solution. Drugs were administered subcutaneously in a 1 ml/kg volume. All doses refer
to the salt form for these drugs. Nicotine was administered 10 minutes and naltrexone
was administered 15 minutes before animals were placed into the apparatus for
conditioning.
Apparatus. Two standard two-chamber shuttleboxes (18.4 cm x 22.9 cm x 16.5
cm for each chamber), constructed with stainless steel and Plexiglas, with tilting grid
floors were used (Med-Associates Inc., St. Albans, VT). Each shuttle box featured a
guillotine door between the two chambers that could be opened or remain closed as
required by the experimenter. The left-hand chambers’ floors consisted of bare
horizontal stainless steel floor bars, while the right-hand chambers’ floors had wire-

18

screen flooring on top of the floor bars to give each chamber a different tactile stimulus.
The bedding pans for the left-hand chambers contained corncob bedding, and the righthand chambers’ bedding pans contained pine shavings, giving each chamber a different
odor. The left-hand chambers’ clear Plexiglas walls and ceilings were covered with black
cloth hoods, while the walls of the right-hand chambers were not covered or altered at all,
thus giving each chamber different visual stimuli. Shuttle boxes were housed in soundattenuated cubicles equipped with fans for ventilation and masking noise. All chambers
were lit by 20 amp interior bulbs during all conditioning and testing sessions. Data were
collected using Med PC version 4 for Windows (Med-Associates Inc.).
Procedure. In this experiment, a total of 40 animals were assigned to 5 groups,
based on an assigned drug condition, with each group consisting of 8 animals. Animals
were selected for each group (N = 8) in a counter balanced manner by body weight. The
drug conditions were nicotine (0.8 mg/kg), naltrexone (1.0 mg/kg), and naltrexone (3.0
mg/kg), as well as two 0.9% physiological saline conditions, which served as the vehicle
controls for nicotine and naltrexone, respectively. The nicotine dose was selected based
upon the work of Calcagnetti and Schechter (1994), who observed a place preference for
nicotine in male Sprague-Dawley rats at this dosage. Naltrexone dosages used in this
study were selected based upon the methods and findings of several previous studies
involving naltrexone and rats, including Olmstead and Burns (2005), Varashin,
Wazlawik, and Morato (2005), Czachowski and Delory (2009), and Liu et al. (2009).
The first phase of the conditioned place preference procedure consisted of
acclimating animals to the study environment by bringing the animals' home cages into
the testing environment for 2 hours a day for two consecutive days. Next, the animals
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were allowed to freely explore both chambers of the shuttle box during 10-minute
“baseline” sessions for 3 consecutive days. The amount of time spent on each side was
recorded in order to determine each animal’s preferred compartment. Preference was
determined by recording the number of seconds spent by each animal per compartment
and then taking the mean of these times across the three baseline sessions.
Following this, 30-minute drug and saline pairing sessions were conducted for 8
consecutive days, with saline (control) or drug given on alternating days. The doors
between chambers were closed at all times during pairing sessions so that each animal
remained in the intended chamber. On “control” days, each animal was placed in its
preferred chamber and on drug days, each animal was placed in its non-preferred
chamber. For animals assigned to the saline treatment condition, as a control group for
either nicotine or naltrexone, saline was given every day in the same alternating fashion
(i.e., saline was pairing with both the preferred and non-preferred chamber). This is
consistent with the biased conditioned place preference procedure set forth by Calcagnetti
and Schechter (1994), in which the drug is paired with the animal’s non-preferred
chamber as determined by baseline measurements (as opposed to the unbiased procedure,
in which no baseline preference is determined and drugs are paired with chambers as
determined by the researcher) On the day immediately following the final pairing
session, a test session was conducted, which consisted of allowing the animals to freely
explore the shuttle box with the guillotine door open for 10 minutes with no pre-session
injection.
In Experiment 1, ten animals were studied at a time. For instance, animals tailmarked “1” through “10” were run through the experiment first (animals were assigned
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identification numbers arbitrarily), followed by animals “11” through “20,” and so forth.
This was done due to the time constraints of the researcher’s schedule, and the fact that
testing all animals in the experiment simultaneously would have been unfeasible with
only two shuttleboxes. Shuttleboxes were cleaned at the end of each daily session, and
were spot-cleaned as needed between animals (for instance, if an animal defecated while
in the shuttlebox, the feces would be removed before the next animal entered). This was
the standard procedure during all baseline, drug pairing, and testing sessions.
Data Analysis. The dependent variables for this study consisted of time (s) spent
in the non-preferred compartment and a percentage based on the time spent in the nonpreferred compartment after pairing compared to time spent in the non-preferred
compartment before pairing. Data were calculated as means (+/- standard error of the
mean [SEM]). A between groups analysis of variance (ANOVA) was conducted for
naltrexone, an independent samples t test was conducted for nicotine, and a dependent
samples t-test was used to compare preference before pairing vs. preference after pairing.
All analyses were conducted using GraphPad Prism version 6.0 for Windows (GraphPad
Prism, La Jolla, CA).
Experiment 2
Subjects. This experiment was conducted following an inability to establish a
conditioned place preference for nicotine in experiment 1. Twenty rats were used in
Experiment 2, and the animals were assigned to a group that received nicotine (0.8
mg/kg) on drug conditioning days or to a control group that received saline every day
during conditioning. All other animal care conditions were the same as in experiment 1.

21

Drugs. Only nicotine hydrochloride (0.8 mg/kg; Sigma-Aldrich) and 0.9%
physiological saline were used in experiment 2. See experiment 1 for further
information.
Apparatus. The shuttle boxes used in experiment 1 were used for this
experiment. However, in this experiment, the black-hood that covered the left-hand
chamber was replaced with vertical black lines on the walls and no covering on the
ceiling. The black lines were printed on white paper, which was trimmed to fit the shuttle
box walls. See experiment 1 for all other details for this apparatus.
Procedure. The purpose of this experiment was to determine if we could
establish a conditioned place preference for nicotine by adjusting the appearance of the
left-hand compartment. Otherwise, the procedures described in experiment 1 were
identical those used for experiment 2.
Data Analysis. The data analysis procedures described in experiment 1 were
identical to those used for experiment 2.
Experiment 3
Subjects. This experiment was performed after a conditioned place preference
for nicotine was found in experiment 2, which used a different appearance for the nonpreferred compartment than in experiment 1. Forty animals were used for experiment 3,
and were assigned to the following four conditions (N = 10): naltrexone (3.0 mg/kg) +
saline, saline + nicotine (0.8 mg/kg), saline + saline, and naltrexone (3.0 mg/kg) +
nicotine (0.8 mg/kg). All animal care conditions were the same as used in Experiments 1
and 2.
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Drugs. Nicotine hydrochloride (0.8 mg/kg; Sigma-Aldrich), naltrexone
hydrochloride (3.0 mg/kg; Sigma-Aldrich), and 0.9% physiological saline were used in
experiment 3. Pretreatment times were identical to those in the first two experiments (15
minutes for naltrexone, and 10 minutes for nicotine). For instance, in the case of the
“naltrexone + nicotine” group, naltrexone was administered 15 minutes prior to being
placed into the shuttle box for training, with nicotine then being administered 5 minutes
after the naltrexone injection (10 minutes before being placed into the shuttle box). In the
“saline + nicotine” group, saline took the place of naltrexone and was administered 15
minutes prior to placing the subject in the shuttle box; in the “naltrexone + saline” group,
saline took the place of nicotine and was administered 10 minutes prior to the training
session. In the “saline + saline” group, the first saline injection was given in lieu of
naltrexone (15 minutes before training initiation), and the second saline injection was
given in lieu of nicotine (administered at the 10-minute mark). See Experiment 1 for
further information.
Apparatus. All apparatus conditions in this experiment were identical to those in
Experiment 2.
Procedure. The conditioned place preference procedures used for experiment 3
were the same as those used for experiments 1 and 2.
Data Analysis. A one-way between groups ANOVA was used to assess potential
differences between these treatment conditions. Otherwise, the data analysis procedures
used for experiment 3 were same used for experiment 1.
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Results
Experiment 1
Baseline. During the 600-second baseline sessions, subjects spent a mean of
289.67 s (+/- SEM=12.74) (48.28% of the total time) in the left-hand chamber and a
mean of 297.64 s (+/- SEM = 12.81) (49.61% of the total time) in the right-hand chamber
per session (time spent in the doorway between the two chambers accounts for the
remaining time/percent). After their preferred and non-preferred sides were determined,
it was calculated that each subject spent a mean of 361.95 s (+/- SEM =6.96) (60.33% of
the total time) on its preferred side and an average of 226.19 s (+/- SEM = 6.69) (37.70%
of the total time) on its non-preferred side per baseline session. Of the 40 subjects used
in this experiment, 20 (50%) of them preferred the left-hand chamber and 20 (50%)
preferred the right-hand chamber.
Nicotine Conditioned Place Preference. The data for conditioned place
preference conducted with nicotine are shown in Figure 1. During the test session
following training, a statistical difference was not found between the number of seconds
spent in the saline-paired compartment (M= 304.90 s +/- SEM= 30.89) versus the
nicotine-paired compartment (M = 263.50 s +/- SEM = 35.64), t(14) = 0.88, p > 0.05. A
statistical difference was also not found when comparing the mean time spent in the nonpreferred compartment during baseline sessions (M = 223.80 s +/- SEM = 12.62) to the
mean time spent in the non-preferred compartment after pairing with nicotine (M = 263.5
s +/- SEM = 35.64), t (7) = 1.19, p > 0.05. Finally, an analysis was conducted to
determine if the percentage of time spent in the non-preferred side after pairing compared
to time spent in the non-preferred side before pairing in saline-treated rats versus
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nicotine-treated rats. A statistically significant difference was not found between the
saline-treated rats (M = 153.60% +/- SEM = 20.54) compared to the nicotine-treated rats
(M = 119.10% +/- SEM = 15.78), t (14) = 1.33, p > 0.05.
Naltrexone Conditioned Place Preference. The data for conditioned place
preference conducted with naltrexone are shown in Figure 2. Statistically significant
differences were not found for the time spent in the non-preferred side between the saline
(M = 253.60 +/- SEM =21.78), naltrexone 1.0 mg/kg (M = 233.80 +/- SEM = 34.48), and
naltrexone 3.0 mg/kg (M = 214.40+/- SEM = 40.65) treatment groups, F(2, 21) = 0.35,
p= 0.710. Also, a statistical difference was not found when comparing the mean time
spent in the non-preferred compartment during baseline sessions (M = 243.30 s +/- SEM
= 18.52) compared to number of seconds spent in the non-preferred compartment after
pairing with naltrexone 1.0 (M = 233.80s +/- SEM = 34.48), t(7) = 0.25, p > 0.05.
Likewise, a statistical difference was not found when comparing the mean time spent in
the non-preferred compartment during baseline sessions (M = 236.00 s +/- SEM = 16.85)
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compared to number of seconds spent in the non-preferred compartment after pairing
with naltrexone 3.0 (M = 214.40 s +/- SEM = 40.65), t (7) = 0.54, p > 0.05. Finally, an
analysis of variance was conducted on the percent change in time spent in the nonpreferred side from before pairing to after pairing for rats in the saline group (M =
117.00% +/- SEM = 10.75), the naltrexone 1.0 group (M = 101.20% +/- SEM = 17.46),
and the naltrexone 3.0 group (M = 93.72% +/- SEM = 19.46). The results of the analysis
did not show a statistically significant difference, F (2, 21) = 0.53, p = 0.595.
Experiment 2
Baseline. During the baseline sessions, subjects spent an average of 243.88 s (+/SEM = 15.93) (40.65% of the time) in the left-hand chamber and an average of 342.87 s
(+/- SEM = 15.95) (57.14%) in the right-hand chamber. After their preferred and nonpreferred sides were determined, it was calculated that each subject spent an average of
361.15 s (+/- SEM = 10.93) (60.19%) on its preferred side and an average of 225.45 s
(+/- SEM = 11.05) (37.58%) on its non-preferred side per baseline session. Out of the 20
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subjects used in this experiment, 5 (25%) of them preferred the left-hand chamber and 15
(75%) preferred the right-hand chamber.
Nicotine Conditioned Place Preference. The data for conditioned place
preference conducted with nicotine are shown in Figure 3. During the test session
following training, the number of seconds spent in the saline-paired compartment (M=
200.40 s +/- SEM= 17.17) was significantly less the number of seconds spent in the
nicotine-paired compartment (M= 271.00 s +/- SEM = 15.31), t(18) = 3.07, p < 0.05.
The mean time spent in the non-preferred compartment during baseline sessions (M =
216.50 s +/- SEM = 19.31) was significantly less than the amount of time spent in the
non-preferred compartment after pairing with nicotine (M = 271.00 s +/- SEM = 15.31),
t(18) = 2.21, p < 0.05.
Experiment 3
Baseline. During the baseline sessions, subjects spent an average of 262.86 s (+/SEM = 6.98) (43.81% of the time) in the left-hand chamber and an average of 324.08 s
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(+/- SEM = 6.77) (54.01%) in the right-hand chamber per session. After their preferred
and non-preferred sides were determined, it was calculated that each subject spent an
average of 336.80 s (+/- SEM = 4.79) (56.13%) on its preferred side and an average of
250.2 s (+/- SEM = 4.84) (41.70%) on its non-preferred side per baseline session. Of the
40 subjects used in this experiment, 7 (17.5%) of them preferred the left-hand chamber
and 33 (82.5%) preferred the right-hand chamber.
Naltrexone + Nicotine. The data for conditioned place preference conducted
with nicotine paired with naltrexone are shown in Figure 4. An analysis of variance did
not show a significant difference for the number of seconds spent in the non-preferred
side between the treatment groups, F(3, 36) = 1.505, p = 0.230. A mixed two-factor
analysis of analysis of variance using training (before and after) as a within subjects
factor and treatment group as a between groups factor revealed a statistically significant
28

increase in time spent in the nonpreferred compartment after training compared to before
training (F[1,35] = 4.22, p = 0.048), but no statistically significant differences for the
treatment factor (F[3, 35] = 1.95, p = 0.140) or an interaction effect (F[3, 35] = 1.48, p =
0.089).
Discussion
The present study reported on the effects of the opioid receptor antagonist
naltrexone on the ability of nicotine to produce a conditioned place preference, a model
for the incentive salience theory of drug addiction. In the first experiment, acute repeated
administration of nicotine did not produce a statistically significant place preference, and
acute repeated administration of two different doses of naltrexone also did not produce a
statistically significant place preference. In the second experiment, after altering the
visual stimuli in the shuttle boxes, acute repeated administration of nicotine did produce a
statistically significant conditioned place preference. In the third experiment nicotine
failed to produce a significant place preference; thus, a potential reversal of a nicotine
place preference by naltrexone could not be evaluated.
The potential to demonstrate a conditioned place preference for nicotine in
rodents has previously been established in several studies, including Calcagnetti and
Schechter (1994), who used male Sprague-Dawley rats (as we chose to use in the present
study), as well as by Walters et al. (2005), Walters et al. (2006), and Smith et al. (2012),
who all used mice. However, Calcagnetti and Schechter (1994) stated that nicotine may
not produce conditioned place preference as reliably as opioids or as other stimulant
drugs do, noting that a few studies from the 1980s and early 1990s either failed to
demonstrate nicotine place preference or found a nicotine place aversion. This
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unpredictability has been echoed more recently by Natarajan, Wright, and Harding
(2011), who note that studies throughout the early 2000s have also produced conflicting
results on the ability of nicotine to produce a conditioned place preference. Also
relevant to this discussion is the idea of pretreating animals with drugs to develop
tolerance prior to an experiment. This practice, in theory, would make the studies with
animal subjects more closely analogous to humans that were heavy smokers. Zarrindast
et al. (2003) used a different approach for studying nicotine place preference by treating
mice with nicotine daily for 12 consecutive days prior to conducting conditioned place
preference procedures in order to establish a tolerance to the aversive effects of nicotine
prior to initiating the conditioned place preference procedure. They were able to establish
a place pereference with nicotine and were able to block the nicotine place preference
with naloxone. Thus, future research involving nicotine and a conditioned place
preference paradigm may wish to consider this option.
Also, previous studies have used a variety of different place preference apparatus
setups, with some choosing to use three-compartment shuttle boxes (and thus employing
an unforced choice procedure), and other studies utilized the forced-choice procedure
similar to the two-compartment shuttle boxes used in the present study. For example,
Calcagnetti and Schechter (1994), Walters, et al. (2006), Natarajan, Wright, and Harding
(2011), and Smith, et al. (2012) all used three-compartment shuttle boxes, while
Zarrindast, et al. (2003) and Walters, et al. (2005) used a two-compartment apparatus
(nearly identical to the one we employed in this study), and Olmstead and Burns (2005)
used a two-compartment apparatus with a tunnel between the compartments. It should be
noted that there appears to be no consensus on which type of place preference apparatus
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configuration is the best option to use for conditioned place preference. However, the
primary concern with the forced choice procedure (as we employed in the current study)
is the potential of unintentionally or unknowingly creating a bias for the side of the
shuttlebox that an animal is placed into at the beginning of the testing session (Prus,
James, & Rosecrans, 2009). This issue was not anticipated or controlled for in the
current study, so it is possible that a compartment bias due to initial placement may have
confounded the results, and future research in this area may wish to strongly consider
employing an unforced choice procedure instead to avoid this potential bias.
Prior to Experiment 1, we had decided to use a black cloth hood over the
Plexiglas walls and ceiling of one chamber, with nothing covering the clear walls and
ceiling of the opposite chamber. This configuration was similar to several previous
conditioned place preference studies. For instance, Calcagnetti and Schechter (1994)
used a white light bulb and had metal bars on the floor in one chamber (much like the
apparatus used in the present study), but used a red light bulb and a black plastic floor in
the opposite chamber to make it darker, and Natarajan, Wright, and Harding (2011)
employed a wooden shuttle box with one main compartment painted white and the other
painted black.
However, after the completion of Experiment 1, in which nicotine did not
establish a conditioned place preference, we decided to re-evaluate our methods. Upon
re-examining a variety of conditioned place preference literature, we discovered that one
phenomenon that can be of concern to researchers in conditioned place preference studies
is that of compartment preference bias, in which animals tend to prefer one compartment
over the other due to its’ environment being noticeably more “comfortable” to them. For
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instance, in Zarrindast and colleagues’ 2003 study, which employed an apparatus with
one compartment painted white and the other black, all animals preferred the black side.
However we did not have statistically significant evidence of compartment bias in
Experiment 1. In fact, the opposite seemed to be true, as the left-side (50%) vs. right-side
(50%) baseline preferences were perfectly unbiased. This led a concern that perhaps the
stimuli in each compartment were not distinct enough, and thus the animals were not able
to effectively discriminate between compartments (essentially the exact opposite of
compartment preference bias).
Thus, we decided that it would be prudent to consider some of the different
methods used in previous conditioned place preference studies to see if we could find an
alternative that would increase the stimulus distinction between the two chambers. Smith
et al. (2012) utilized the same setup for their three-compartment shuttle box as Schindler,
Li, and Chavkin (2010), in which one main compartment had vertically-oriented
alternating white and black stripes and the opposite chamber had horizontal-oriented
stripes, with the center chamber painted plain white. We decided to use a modified
version of this white-and-black-stripes stimulus for our two-chamber shuttle boxes,
similar to what Olmstead and Burns (2005) used in their study involving opioids and
conditioned place preference (see Methods section for further details). Our subsequent
demonstration of a place preference for nicotine in Experiment 2 led to the use of this
equipment set up for experiment 3. We cannot conclusively state whether or not altering
the visual stimulus on one side of our shuttle boxes directly led to establishing
conditioned place preference in Experiment 2, but it is, at the very least, a noteworthy
coincidence.
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Walters et al. (2005) found that conditioned place preference for nicotine could be
blocked in kappa-opioid receptor knockout mice by pretreatment with the opioid receptor
antagonist naloxone on the test day following conditioning. Smith et al. (2012) were able
to block an increase in place preference for nicotine in mice following forced swim stress
with the opioid receptor antagonist norbinaltorphimine, although they found that
norbinaltorphimine did not block nicotine place preference in animals not subjected to
stress prior to testing. We were unable to demonstrate the ability of naltrexone to block
place preference for nicotine in this experiment due to the lack of a significant place
preference effect by nicotine in experiment 3. It is possible that our findings may be due
to our particular combination of opioid receptor antagonist (naltrexone), rodent (SpragueDawley rats), type of apparatus (two-chamber forced-choice), and lack of any forced
stress method prior to testing. Another possibility is that the nicotine dosage of 0.8
mg/kg may have been too low – we felt that our observation of nicotine place preference
at that dosage in Experiment 2 indicated that it was adequate, but we did not find a place
preference at that dosage in two out of the three experiments. Additionally, it is possible
that having larger group sizes, and thus increased statistical power, could have resulted in
statistically significant differences between groups in Experiment 3.
The idea of using manipulative techniques such as forced stress in order to obtain
a preference for nicotine echoes the finding in self-administration studies that rats will
not learn to self-administer nicotine acutely due to the drug’s initial adverse effects (Prus,
2014). For instance, in order to induce nicotine self-administration, Boules, Oliveros,
Liang, et al. (2011) first trained rats to obtain sucrose pellets via lever-pressing before
exchanging the sucrose reward with nicotine injections. Another variable to consider in
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nicotine research is the fact that, in addition to nicotine, tobacco also contains MAO
inhibitors that are thought be instrumental in enhancing the rewarding effects of nicotine
by increasing dopamine levels in the nucleus accumbens. For instance, Villegier,
Lotfipour, McQuown, et al. (2007) found that rats self-administered nicotine after being
injected with the non-selective MAO inhibitor tranylcypromine, and further research by
Villegier, Belluzzi, and Leslie (2011) suggests that MAO inhibition may also increase
serotonin levels.
Interestingly, our findings do somewhat parallel those of Liu et al. (2009), who
found that while naltrexone did attenuate post-extinction reinstatement of nicotineseeking in rats in a self-administration paradigm, it did not acutely affect selfadministration behavior. As it relates to clinical applications, the findings of Liu et al.
(2009) would seem to suggest that naltrexone may be more efficacious as a “relapse
prevention” treatment for abstinent former tobacco users than as an intervention for
current tobacco users. This idea is supported by the findings of Jackson, et al. (2010),
who concluded that kappa opioid receptors are clearly involved in mediating nicotine
withdrawal symptoms. These findings also fall in line with the findings of studies
involving naltrexone’s effect on other non-opioid drugs of abuse. For instance, Weerts et
al. (2008) found that naltrexone almost completely inhibited mu-opioid receptors in their
study of recently abstinent alcohol-dependent humans (a stage of the treatment process
during which relapse prevention is the primary concern). Likewise, Srisurapanont and
Jarusaraisin’s (2005) meta-analysis found that while naltrexone did not decrease
discontinuation of substance abuse treatment for alcohol-addicted humans, it did
significantly decrease the incident of relapse. The finding that opioid receptors appear to
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be involved in the expression of withdrawal symptoms in non-opioid drugs of abuse in
animals models, along with indications that naltrexone may be effective as a smoking
cessation aid in studies of human subjects (King & Meyer, 2000; Krishnan-Sarin,
Meandzija, & O’Malley, 2003; Rustkalis et al., 2005; Ray et al., 2007) make this an
intriguing area of study that has yet to be fully explored.
Conclusion
In summary, the purpose of the present study was to further investigate the effect
of opioid receptor antagonism on nicotine in animal subjects. A conditioned place
preference procedure was employed because this paradigm is thought to be an indicator
of incentive salience, which is thought to be an important factor in the withdrawal
symptoms experienced by recently abstinent tobacco users suffering from nicotine
abstinence syndrome. After not finding a place preference for nicotine in the first
experiment, a place preference for nicotine was established after changing the appearance
of the experimental chamber in the second experiment. However, this configuration did
not lead to a significant place preference for nicotine in the third experiment. Thus, the
present study was not able to demonstrate any significant effects of naltrexone on
nicotine-induced place preference.
While our results from the current study did not find any direct support for this
idea, previous research suggests that opioid receptor antagonists may be a potential
treatment for nicotine addiction. An advantage of evaluating opioid receptor antagonists
is that two of these compounds (naloxone and naltrexone) are already FDA-approved for
use in humans with opioid addiction and lead to relatively few adverse effects in humans.
While clinicians may attempt to use naltrexone off-label for treating nicotine addiction,

35

the FDA will likely not allow clinical trials for opioid antagonist use in nicotine addiction
without supporting data from animal models. Previous literature indicates that there are
alternative approaches to studying nicotine in a conditioned place preference procedure
and these other procedures should be examined in future studies.
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APPENDIX A
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APPENDIX B

Exp 1 Nicotine Nonpreferred
Saline
Nicotine
386
417
280
179
152
300
322
314
348
275
231
415
300
338
89
201

NTX_Saline
271
170
312
246
241
167
339
283

Exp 1 Nicotine Change
Before After
386
232
280
248
152
231
322
229
348
255
231
141
300
240
89
214

Exp 1 Nicotine- Saline percent changed to nonpreferred
Saline
Nicotine
ntx_saline
184.5133
166.3793
169.0229
77.15517
112.7517
86.88245
153.8462
65.80087
118.3312
251.8717
140.6114
102.3578
128.5047
136.4706
106.3235
169.6185
164.218
84.48566
183.3635
125.1739
155.2672
80.07968
41.65367
113.5027
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Exp 1 Naltrexone Nonpreferred
Saline Ntx 1.0 Ntx 3.0
271
210
341
170
66
70
312
246
154
246
149
304
241
365
232
167
209
134
339
300
374
283
325
106

Exp 1 Naltrexone Change 1.0
Before After
210
294
66
245
246
151
149
234
365
288
209
268
300
182
325
284

Exp 1 Naltrexone Change 3.0
Before After
341
282
70
250
154
268
304
153
232
236
134
229
374
288
106
182
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Exp 1 Naltrexone - Saline percent changed nonpreferred
Saline Ntx 1.0 Ntx 3.0
169.0229 71.42857 120.7792
86.88245 26.90217 27.96272
118.3312 162.9139 57.53425
102.3578 63.67521 198.6928
106.3235 126.883 98.16644
84.48566 77.98508 58.51529
155.2672 165.1376 129.8611
113.5027 114.3025 58.24176

Exp 2 Nicotine Nonpreferred
Nicotine
Saline
218
233
302
201
253
126
328
229
255
227
339
216
249
180
280
304
185
162
301
126

Exp 2 Nicotine Change
Before After
199
218
279
302
89
253
251
328
189
255
231
339
282
249
205
280
163
185
277
301
51

Exp 3 Nicotine + Naltrexone Nonpreferred
Naltrexone +
Saline +
Saline + Saline
Saline
Nicotine
205
366
102
310
221
211
253
142
113
244
275
256
251
133
281
302
245
262
386
167
367
406
199
198
231
134
49
211
455
257

Exp 3 Nicotine + Naltrexone Change
Naltrexone +
Saline + Saline
Saline
-129
140
-48
-64
-97
-11
-36
-15
47
-139
15
-1
76
-57
-55
-80
-145
-133
10

Saline +
Nicotine
-34
107
-29
-17
-12
15
110
130
-50
-30
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Naltrexone +
Nicotine
232
190
200
263
132
142
199
170
394
106

Naltrexone +
Nicotine
-29
-86
-16
34
-101
-131
-27
-97
134
-128

Exp 3 Nicotine + Naltrexone Two Factor Before After
Saline + Saline
A:Y A:Y2 A:Y3 A:Y4 A:Y5 A:Y6 A:Y7 A:Y8 A:Y9 A:Y10
1
257
Before 102 211 113 256 281 262 367 198 49
After 231 259 210 292 234 247 291 253 194 247
Naltrexone + Saline
B:Y B:Y2 B:Y3 B:Y4 B:Y5 B:Y6 B:Y7 B:Y8 B:Y9 B:Y10
1
Before 366 221 142 275 133 245 167 199 134
After 226 285 153 290 272 246 224 279 267
Saline + Nicotine
C:Y C:Y2 C:Y3 C:Y4 C:Y5 C:Y6 C:Y7 C:Y8 C:Y9 C:Y10
1
Before 205 310 253 244 251 302 386 406 231 211
After 239 203 282 261 263 287 276 276 281 241
Naltrexone + Nicotine
D:Y D:Y2 D:Y3 D:Y4 D:Y5 D:Y6 D:Y7 D:Y8 D:Y9 D:Y10
1
Before 232 190 200 263 132 142 199 170 394 106
After 261 276 216 229 233 273 226 267 260 234
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